Adaptimmune
Founded 2008 · 128 employees on LinkedIn · 5 known investors
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
Investors · 5
Competitors · 4
by search overlap
Cancerresearchuk98 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Medscape93 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Massive Bio81 shared keywordsMassive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
American Cancer Society (ACS)76 shared keywordsThe American Cancer Society is a nonprofit cancer-fighting organization that combats cancer through advocacy, research, and patient support. It provides information, guidance, caregiver resources, screening guidance, and clinical trial navigation for cancer patients, families, and caregivers, and funds cancer research.
Companies competing with Adaptimmune for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Adaptimmune do?
- Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
- Who are Adaptimmune's investors?
- Adaptimmune's investors include Avoro Capital Advisors, Eight Roads Ventures, F-Prime Capital, New Enterprise Associates (NEA), Ridgeback Capital.